What PEARL Actually Changes in Clinical Practice

At a glance

| Detail | Value | |---|---| | Trial name | PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) | | N | 114 | | Intervention | Rapamycin (sirolimus) 5 mg or 10 mg once weekly | | Comparator | Placebo | | Duration | 48 weeks | | Primary endpoint | Self-reported health domains, immune markers, biomarkers of aging | | Key result | Domain-specific quality-of-life improvements; no serious adverse events attributable to rapamycin at either dose |

Why this trial generated so much noise

Rapamycin has extended lifespan in nearly every model organism tested, from yeast to mice. The Interventions Testing Program showed consistent mouse lifespan extension across three independent labs. Longevity clinicians have prescribed it off-label for years, largely on the strength of animal data and mechanistic reasoning about mTOR inhibition. What was missing until PEARL was a properly randomized, placebo-controlled trial in healthy humans asking a simple question: does this do anything measurable, and does it hurt anyone?

Published in Aging Cell in 2024, PEARL enrolled 114 generally healthy adults aged 50 to 85 and randomized them to rapamycin 5 mg/week, 10 mg/week, or placebo over 48 weeks. The trial was partly crowdfunded and run with a participatory design, meaning participants were actively engaged in the research process. That design choice matters for interpreting results.

What the methodology actually looked like

PEARL was a three-arm, double-blind, placebo-controlled trial. Participants were recruited through longevity-focused communities, which introduces a self-selection issue worth flagging. These were health-motivated adults, many already tracking biomarkers, taking supplements, and engaging in structured exercise. They are not a representative sample of the general 50-to-85 population.

The dosing schedule (once weekly, not daily) was chosen to mimic the intermittent mTOR inhibition protocol that showed immune benefits in the Mannick et al. 2014 study of the rapalog everolimus in older adults. Weekly dosing keeps trough levels low, theoretically suppressing mTORC1 while allowing mTORC2 to recover. This distinction matters because chronic daily rapamycin at transplant doses (2 to 5 mg/day) causes well-documented metabolic side effects: dyslipidemia, glucose intolerance, and mouth ulcers. The FDA label for sirolimus lists these prominently in the context of immunosuppression for organ transplant recipients.

The primary endpoints were composites. Self-reported health was measured across multiple domains. Immune markers included standard panels. "Biomarkers of aging" encompassed a range of blood-based measures. The trial was not powered for any single hard endpoint like infection rate, hospitalization, or mortality. This is the most important methodological limitation. Everything downstream of it must be interpreted accordingly.

The HealthRX Clinical Translation Framework for PEARL

We evaluate every longevity trial against four questions before deciding what, if anything, it changes at the point of care.

1. Did it move a hard endpoint? No. PEARL measured self-reported outcomes and surrogate biomarkers. No reduction in infections, fractures, hospitalizations, cancer incidence, or mortality was demonstrated. Self-reported quality-of-life improvements in specific domains are real data, but they sit low on the evidence hierarchy for changing prescribing behavior.

2. Was the safety signal clean enough for off-label use? Mostly yes, with caveats. PEARL reported no serious adverse events attributable to rapamycin at either dose. Mouth ulcers, the most common complaint in transplant-dose rapamycin use, occurred at low rates. Lipid panels and glucose markers did not show clinically meaningful deterioration at 48 weeks. This is genuinely useful data. Prior to PEARL, clinicians prescribing weekly rapamycin were relying on transplant-dose safety data (not applicable) and mouse pharmacokinetics (not directly translatable). Now there is at least one controlled dataset showing 48 weeks of weekly low-dose exposure without major signals.

3. Has any guideline body responded? No. As of mid-2026, no major medical society (AGS, Endocrine Society, AACE, or any national geriatrics body) has issued guidance on rapamycin for aging. The American Federation for Aging Research has acknowledged the trial but has not issued prescribing recommendations. PEARL is too small and too soft-endpoint-driven to trigger guideline changes on its own.

4. Does the trial population match real-world patients asking for this drug? Partially. The participants were health-conscious, predominantly well-educated, and self-selected from longevity communities. The median health status at baseline was already high. This limits generalizability in two directions: the modest improvements may not replicate in less health-optimized populations (ceiling effect in the trial cohort), and the safety profile may not hold in patients with comorbidities, polypharmacy, or metabolic syndrome.

Results that matter, in context

| Outcome | 5 mg/week | 10 mg/week | Placebo | Clinical significance | |---|---|---|---|---| | Self-reported health (composite) | Improved in select domains | Improved in select domains | Stable | Modest; no validated longevity-specific PRO instrument exists | | Mouth ulcers | Low incidence | Slightly higher | Baseline | Consistent with dose-dependent mucosal sensitivity | | Lipid changes | No clinically significant shift | No clinically significant shift | No change | Reassuring vs. transplant-dose data | | Fasting glucose | Stable | Stable | Stable | Reassuring vs. transplant-dose data | | Serious adverse events | None attributed | None attributed | None attributed | Key finding for off-label safety argument |

The quality-of-life improvements were domain-specific, not global. Participants did not uniformly feel better across all measures. Some domains showed improvement while others did not separate from placebo. This pattern is consistent with a real but modest signal rather than a significant clinical effect.

What PEARL did not answer

The trial leaves several critical questions unresolved. These are not minor gaps. They are the questions that would need answers before any responsible guideline update.

Duration of benefit. Forty-eight weeks is a start. Rapamycin's proposed mechanism for longevity involves autophagy upregulation, improved proteostasis, and immune remodeling. These processes operate on timescales of years, not months. Whether the quality-of-life signal persists, grows, or fades after year one is unknown.

Hard clinical endpoints. No infection data worth powering for. No cancer incidence. No cardiovascular events. No mortality. A trial of 114 people over 48 weeks cannot answer these questions, and PEARL was never designed to. But these are the endpoints that move clinical practice.

Dose optimization. PEARL tested two doses. The longevity clinic community uses a range of protocols: 1 mg daily, 3 mg weekly, 5 mg biweekly, 6 mg weekly with grapefruit juice to boost bioavailability. PEARL does not resolve which protocol, if any, is optimal. The Mannick et al. follow-up work on everolimus used different dosing entirely, making cross-study dose comparison difficult.

Drug interactions and comorbid populations. Rapamycin is a CYP3A4 substrate with significant interaction potential. The sirolimus prescribing information lists dozens of interactions. PEARL enrolled healthy adults on minimal medications. Patients asking longevity clinicians for rapamycin often take statins, metformin, antihypertensives, and supplements that may interact. No controlled data exist for these combinations at longevity doses.

What should change in practice today

Honestly? Very little at the institutional level. A great deal at the conversational level.

For clinicians already prescribing rapamycin off-label: PEARL provides the first controlled safety dataset to reference when discussing risk with patients. Before this trial, the conversation was "mouse data is strong, transplant data doesn't apply, and we have case series." Now it includes "a 48-week RCT of 114 healthy adults showed no serious adverse events at 5 or 10 mg weekly." That is a meaningful upgrade in informed consent quality, even if it does not constitute a prescribing indication.

For clinicians not prescribing rapamycin: PEARL does not create a reason to start. The evidence base remains pre-clinical plus one modest RCT with soft endpoints. The risk-benefit calculus for a healthy 55-year-old asking about rapamycin has shifted slightly toward "less risky than we feared" but has not moved on the "proven benefit" axis.

For patients: The trial confirms that weekly low-dose rapamycin is probably not dangerous over one year in healthy adults. It does not confirm that it extends lifespan, prevents disease, or produces benefits large enough to justify cost and monitoring. Patients should understand that taking rapamycin for longevity today remains an experiment on themselves, now with slightly better safety guardrails.

The larger evidence trajectory

PEARL sits within a growing body of early-phase longevity pharmacology research. The TRIMS trial examined topical rapamycin for skin aging. The Mannick everolimus studies examined immune function in older adults. The dog aging project has tested rapamycin in companion animals with mixed early results.

What is missing from the entire field is a large (N > 500), multi-year trial with hard endpoints. PEARL's value is that it makes such a trial more plausible by demonstrating acceptable safety and feasibility of recruitment. It is a stepping stone, not a destination.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Kaeberlein M, et al. "Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL): a randomized clinical trial." Aging Cell. 2024. PubMed
2. Mannick JB, et al. "mTOR inhibition improves immune function in the elderly." Science Translational Medicine. 2014;6(268):268ra179. PubMed
3. Mannick JB, et al. "TORC1 inhibition enhances immune function and reduces infections in the elderly." Science Translational Medicine. 2018;10(449):eaaq1564. PubMed
4. FDA. Sirolimus (Rapamune) prescribing information. FDA Label
5. Harrison DE, et al. "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." Nature. 2009;460(7253):392-395. PubMed
6. Chung CL, et al. "Topical rapamycin reduces markers of senescence and aging in human skin." GeroScience. 2022. PubMed